CStone Pharmaceuticals (HKEX:2616), a China-based biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, announced on Sunday the first disclosure of preliminary Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress.
According to CStone, this represents the first known clinical data publication of a PD-1/VEGF/CTLA-4 trispecific antibody to date.
The multi-regional phase I study in Australia and China is evaluating the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and anti-tumour activity of CS2009 in patients with advanced solid tumours. As of the data cutoff date, 72 patients with advanced solid tumours were treated across six dose levels (DL1-6, 1-45 mg/kg), and 72.2% remain on treatment.
Over 51% had previously received immuno-oncology (IO) therapies. The median follow-up was only 1.9 months (range 0.1 to 6.7 months) at data cutoff.
CStone reported favourable safety and tolerability: dose escalation was completed with no dose-limiting toxicity reported and the maximum tolerated dose was not reached.
As of the cutoff date, the overall follow-up duration remained limited, particularly in higher-dose cohorts where the majority of patients had yet to reach the protocol-specified time point of post-baseline tumour assessment. Data shows that 49/72 patients underwent at least one post-baseline tumour assessment by data cutoff. Despite limited follow-up duration, anti-tumour activity was observed across all dose levels with dose-dependent uptrend, and promising efficacy signals were observed across multiple tumour types.
CStone has initiated a Phase II dose expansion study in first-line patients with selected tumour types for dose optimisation and to generate data supporting registration trials in first-line NSCLC and other tumours as monotherapy or in combination therapies.
CStone announces Phase I CS2009 data at ESMO 2025
Antengene reveals ATG-022 clinical data at ESMO 2025
Sichuan Kelun-Biotech presents positive Phase 3 trial results for sac-TMT
Clarity Pharmaceuticals signs copper-67 supply agreement with Nusano
SOPHiA DDM Digital Twins launched to simulate patient outcomes and support oncology decisions
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Privo Technologies reports progress in oral cancer trial
Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference